Glenmede Investment Management LP Has $45.31 Million Stock Holdings in Merck & Co., Inc. $MRK

Glenmede Investment Management LP trimmed its stake in Merck & Co., Inc. (NYSE:MRK) by 14.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 539,875 shares of the company’s stock after selling 89,706 shares during the quarter. Glenmede Investment Management LP’s holdings in Merck & Co., Inc. were worth $45,312,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Darwin Wealth Management LLC grew its stake in shares of Merck & Co., Inc. by 237.4% in the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after buying an additional 216 shares in the last quarter. Kilter Group LLC acquired a new position in Merck & Co., Inc. during the second quarter worth $27,000. Barnes Dennig Private Wealth Management LLC raised its position in Merck & Co., Inc. by 302.3% during the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after acquiring an additional 266 shares in the last quarter. Bare Financial Services Inc raised its position in Merck & Co., Inc. by 51.9% during the second quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock worth $29,000 after acquiring an additional 125 shares in the last quarter. Finally, Evolution Wealth Management Inc. acquired a new stake in Merck & Co., Inc. in the second quarter valued at $31,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Unusually large call buying: traders bought ~672,962 call options on Friday (a ~1,339% jump vs. typical daily call volume), signaling heavy bullish speculation or hedging interest that can lift near-term implied volatility and upside pressure on MRK shares.
• Positive Sentiment: Phase 3 WELIREG data and regulatory filings deepen Merck’s oncology growth story — new Phase 3 results for belzutifan (WELIREG) combos with KEYTRUDA or LENVIMA show meaningful improvement in RCC; FDA filings with priority reviews/PDUFA dates for 2026 could expand label and revenue runway. Merck’s WELIREG Kidney Cancer Trials Deepen Oncology Growth Story
• Positive Sentiment: Analyst upgrades/price-target raises: Wells Fargo raised its price target to $150 and assigned an overweight rating, and Leerink lifted its target as well — both moves increase institutional demand signals and implied upside for MRK. Benzinga Leerink Raises Merck & Co. Inc. (MRK) Price Target
• Positive Sentiment: RBC Capital maintains a Buy rating, reinforcing analyst support and potentially bolstering demand from long-only managers. RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
• Positive Sentiment: Bullish price commentary: coverage and price-target pieces (e.g., 247WallStreet) argue broader upside (some scenarios to $150) based on drug pipeline potential, supporting a favorable narrative among momentum investors. Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
• Neutral Sentiment: Market report on Ovidrel/Ovitrelle highlights expanding fertility market opportunities that could be a modest long-term tailwind for related Merck products, but it’s not an immediate revenue catalyst. Ovidrel or Ovitrelle Market Research Report 2026
• Neutral Sentiment: Misc. coverage items (e.g., stock-picking lists and unrelated biotech moves) mention MRK in broader contexts but are unlikely to materially move the stock on their own. 1 Unpopular Stock That Deserves Some Love and 2 We Avoid ImmunityBio Stock Soars 295% YTD

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on MRK shares. UBS Group lifted their price objective on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. BMO Capital Markets raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and upped their target price for the company from $82.00 to $130.00 in a report on Thursday, December 18th. Morgan Stanley raised their target price on shares of Merck & Co., Inc. from $100.00 to $102.00 and gave the company an “equal weight” rating in a research note on Friday, December 12th. Cantor Fitzgerald lifted their price target on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Finally, Scotiabank boosted their price target on Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “sector outperform” rating in a research report on Thursday, December 4th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $126.81.

Insider Activity at Merck & Co., Inc.

In related news, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the business’s stock in a transaction on Friday, February 6th. The stock was sold at an average price of $121.87, for a total value of $1,828,050.00. Following the completion of the sale, the insider directly owned 21,197 shares in the company, valued at $2,583,278.39. The trade was a 41.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Jennifer Zachary sold 121,573 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total value of $14,485,422.95. Following the completion of the transaction, the executive vice president directly owned 68,916 shares in the company, valued at approximately $8,211,341.40. This represents a 63.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 320,176 shares of company stock valued at $38,281,735. Insiders own 0.13% of the company’s stock.

Merck & Co., Inc. Price Performance

NYSE:MRK opened at $115.61 on Friday. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $125.14. The company has a market cap of $285.84 billion, a P/E ratio of 15.88, a P/E/G ratio of 2.24 and a beta of 0.27. The firm’s fifty day moving average price is $115.26 and its two-hundred day moving average price is $99.58. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. The company had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. Merck & Co., Inc.’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be given a dividend of $0.85 per share. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 46.70%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.